Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 4
1991 12
1992 7
1993 22
1994 7
1995 15
1996 42
1997 13
1998 34
1999 35
2000 35
2001 30
2002 36
2003 44
2004 30
2005 46
2006 31
2007 52
2008 36
2009 33
2010 36
2011 40
2012 63
2013 50
2014 52
2015 55
2016 38
2017 47
2018 49
2019 73
2020 80
2021 98
2022 76
2023 60
2024 71
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,339 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Azithromycin for prevention of exacerbations of COPD.
Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, Make B, Marchetti N, Martinez FJ, Madinger NE, McEvoy C, Niewoehner DE, Porsasz J, Price CS, Reilly J, Scanlon PD, Sciurba FC, Scharf SM, Washko GR, Woodruff PG, Anthonisen NR; COPD Clinical Research Network. Albert RK, et al. N Engl J Med. 2011 Aug 25;365(8):689-98. doi: 10.1056/NEJMoa1104623. N Engl J Med. 2011. PMID: 21864166 Free PMC article. Clinical Trial.
The rate of 1-year follow-up was 89% in the azithromycin group and 90% in the placebo group. The median time to the first exacerbation was 266 days (95% confidence interval [CI], 227 to 313) among participants receiving azithromycin, as compared with 174 days (95% C …
The rate of 1-year follow-up was 89% in the azithromycin group and 90% in the placebo group. The median time to the first exacerbatio …
Adjunctive Azithromycin Prophylaxis for Cesarean Delivery.
Tita AT, Szychowski JM, Boggess K, Saade G, Longo S, Clark E, Esplin S, Cleary K, Wapner R, Letson K, Owens M, Abramovici A, Ambalavanan N, Cutter G, Andrews W; C/SOAP Trial Consortium. Tita AT, et al. N Engl J Med. 2016 Sep 29;375(13):1231-41. doi: 10.1056/NEJMoa1602044. N Engl J Med. 2016. PMID: 27682034 Free PMC article. Clinical Trial.
BACKGROUND: The addition of azithromycin to standard regimens for antibiotic prophylaxis before cesarean delivery may further reduce the rate of postoperative infection. We evaluated the benefits and safety of azithromycin-based extended-spectrum prophylaxis in wome …
BACKGROUND: The addition of azithromycin to standard regimens for antibiotic prophylaxis before cesarean delivery may further reduce …
Azithromycin for Poorly Controlled Asthma in Children: A Randomized Controlled Trial.
Ghimire JJ, Jat KR, Sankar J, Lodha R, Iyer VK, Gautam H, Sood S, Kabra SK. Ghimire JJ, et al. Chest. 2022 Jun;161(6):1456-1464. doi: 10.1016/j.chest.2022.02.025. Epub 2022 Feb 22. Chest. 2022. PMID: 35202621 Clinical Trial.
BACKGROUND: Azithromycin has immunomodulatory actions, and its beneficial effects have been demonstrated in asthmatic adults. ...INTERPRETATION: The use of azithromycin in children with poorly controlled asthma resulted in improved asthma control and reduced exacerb …
BACKGROUND: Azithromycin has immunomodulatory actions, and its beneficial effects have been demonstrated in asthmatic adults. ...INTE …
Azithromycin to Prevent Sepsis or Death in Women Planning a Vaginal Birth.
Tita ATN, Carlo WA, McClure EM, Mwenechanya M, Chomba E, Hemingway-Foday JJ, Kavi A, Metgud MC, Goudar SS, Derman R, Lokangaka A, Tshefu A, Bauserman M, Bose C, Shivkumar P, Waikar M, Patel A, Hibberd PL, Nyongesa P, Esamai F, Ekhaguere OA, Bucher S, Jessani S, Tikmani SS, Saleem S, Goldenberg RL, Billah SM, Lennox R, Haque R, Petri W, Figueroa L, Mazariegos M, Krebs NF, Moore JL, Nolen TL, Koso-Thomas M; A-PLUS Trial Group. Tita ATN, et al. N Engl J Med. 2023 Mar 30;388(13):1161-1170. doi: 10.1056/NEJMoa2212111. Epub 2023 Feb 9. N Engl J Med. 2023. PMID: 36757318 Free PMC article. Clinical Trial.
BACKGROUND: The use of azithromycin reduces maternal infection in women during unplanned cesarean delivery, but its effect on those with planned vaginal delivery is unknown. Data are needed on whether an intrapartum oral dose of azithromycin would reduce maternal an …
BACKGROUND: The use of azithromycin reduces maternal infection in women during unplanned cesarean delivery, but its effect on those w …
Intravenous Doxycycline, Azithromycin, or Both for Severe Scrub Typhus.
Varghese GM, Dayanand D, Gunasekaran K, Kundu D, Wyawahare M, Sharma N, Chaudhry D, Mahajan SK, Saravu K, Aruldhas BW, Mathew BS, Nair RG, Newbigging N, Mathew A, Abhilash KPP, Biswal M, Prasad AH, Zachariah A, Iyadurai R, Hansdak SG, Sathyendra S, Sudarsanam TD, Prakash JAJ, Manesh A, Mohan A, Tarning J, Blacksell SD, Peerawaranun P, Waithira N, Mukaka M, Cheah PY, Peter JV, Abraham OC, Day NPJ; INTREST Trial Investigators. Varghese GM, et al. N Engl J Med. 2023 Mar 2;388(9):792-803. doi: 10.1056/NEJMoa2208449. N Engl J Med. 2023. PMID: 36856615 Free PMC article. Clinical Trial.
The incidence with combination therapy was also lower than that with azithromycin (48%), for a risk difference of -14.8 percentage points (95% CI, -23.1 to -6.5; P<0.001). No significant difference was seen between the azithromycin and doxycycline groups (risk di …
The incidence with combination therapy was also lower than that with azithromycin (48%), for a risk difference of -14.8 percentage po …
Effect of Intrapartum Azithromycin vs Placebo on Neonatal Sepsis and Death: A Randomized Clinical Trial.
Roca A, Camara B, Bognini JD, Nakakana UN, Somé AM, Beloum N, Rouamba T, Sillah F, Danso M, Jones JC, Graves S, Jagne I, Getanda P, Darboe S, Tahita MC, Ndure E, Franck HS, Edmond SY, Dondeh BL, Nassa WGJ, Garba Z, Bojang A, Njie Y, Bottomley C, Tinto H, D'Alessandro U; PregnAnZI-2 Working Group. Roca A, et al. JAMA. 2023 Mar 7;329(9):716-724. doi: 10.1001/jama.2022.24388. JAMA. 2023. PMID: 36881034 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the efficacy of intrapartum azithromycin to reduce neonatal sepsis or mortality, as well as neonatal and maternal infections. ...CONCLUSIONS AND RELEVANCE: Azithromycin administered orally during labor did not reduce neonatal sepsis or mortali …
OBJECTIVE: To evaluate the efficacy of intrapartum azithromycin to reduce neonatal sepsis or mortality, as well as neonatal and mater …
Azithromycin in patients with COVID-19: a systematic review and meta-analysis.
Ayerbe L, Risco-Risco C, Forgnone I, Pérez-Piñar M, Ayis S. Ayerbe L, et al. J Antimicrob Chemother. 2022 Feb 2;77(2):303-309. doi: 10.1093/jac/dkab404. J Antimicrob Chemother. 2022. PMID: 34791330 Free PMC article.
BACKGROUND: Azithromycin has been widely used in the management of COVID-19. However, the evidence on its actual effects remains disperse and difficult to apply in clinical settings. This systematic review and meta-analysis summarizes the available evidence to date on the …
BACKGROUND: Azithromycin has been widely used in the management of COVID-19. However, the evidence on its actual effects remains disp …
Azithromycin to Reduce Mortality - An Adaptive Cluster-Randomized Trial.
O'Brien KS, Arzika AM, Amza A, Maliki R, Aichatou B, Bello IM, Beidi D, Galo N, Harouna N, Karamba AM, Mahamadou S, Abarchi M, Ibrahim A, Lebas E, Peterson B, Liu Z, Le V, Colby E, Doan T, Keenan JD, Oldenburg CE, Porco TC, Arnold BF, Lietman TM; AVENIR study group. O'Brien KS, et al. N Engl J Med. 2024 Aug 22;391(8):699-709. doi: 10.1056/NEJMoa2312093. N Engl J Med. 2024. PMID: 39167806 Clinical Trial.
METHODS: We randomly assigned rural communities in Niger to four twice-yearly distributions of azithromycin for children 1 to 59 months of age (child azithromycin group), four twice-yearly distributions of azithromycin for infants 1 to 11 months of age and pl …
METHODS: We randomly assigned rural communities in Niger to four twice-yearly distributions of azithromycin for children 1 to 59 mont …
Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.
Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P, Storey L, Ashton T. Wong C, et al. Lancet. 2012 Aug 18;380(9842):660-7. doi: 10.1016/S0140-6736(12)60953-2. Lancet. 2012. PMID: 22901887 Clinical Trial.
BACKGROUND: Azithromycin is a macrolide antibiotic with anti-inflammatory and immunomodulatory properties. ...Additionally, change in SGRQ total score did not differ between the azithromycin (-5.17 units) and placebo groups (-1.92 units; difference -3.25, 95% CI -7. …
BACKGROUND: Azithromycin is a macrolide antibiotic with anti-inflammatory and immunomodulatory properties. ...Additionally, change in …
Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial.
Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van't Veer NE, Ermens AA, Pelle AJ, Hoogsteden HC, Aerts JG, van der Eerden MM. Uzun S, et al. Lancet Respir Med. 2014 May;2(5):361-8. doi: 10.1016/S2213-2600(14)70019-0. Epub 2014 Apr 15. Lancet Respir Med. 2014. PMID: 24746000 Clinical Trial.
We recorded 84 exacerbations in patients in the azithromycin group compared with 129 in those in the placebo group. The unadjusted exacerbation rate per patient per year was 1.94 (95% CI 1.50-2.52) for the azithromycin group and 3.22 (2.62-3.97) for the placebo grou …
We recorded 84 exacerbations in patients in the azithromycin group compared with 129 in those in the placebo group. The unadjusted ex …
1,339 results

Searches related to "azithromycin"